First Nitrosamine Implementation Oversight Group (NIOG) - meeting with pharmaceutical industry
Date:
31/03/2021
The Nitrosamine Implementation Oversight Group (NIOG) was set up by the European medicines regulatory network to oversee the harmonised implementation of the Article 5(3) CHMP opinion on nitrosamines in human medicinal products.
The NIOG will be the main interface between regulators and industry to agree on topics requiring further scientific discussion.
This is the first meeting of the NIOG with industry stakeholders. The aim is to explain the NIOG's mandate and operating methods, and to future interactions with industry on specific nitrosamine-related topics.
-
List item
Highlights from the Nitrosamine Implementation Oversight Group (NIOG) - industry stakeholders meeting (PDF/143.89 KB)
First published: 12/04/2021 -
List item
Agenda - Nitrosamine Implementation Oversight Group (NIOG) - meeting with pharmaceutical industry (PDF/148.18 KB)
First published: 12/04/2021
EMA/167020/2021 -
List item
Presentation - Means of operation and interaction (PDF/269.77 KB)
First published: 12/04/2021 -
List item
Presentation - Workplan and topics for QWP and SWP IP Meetings (PDF/199.27 KB)
First published: 12/04/2021